Javier Mar1, Jose Errasti2, Myriam Soto-Gordoa3, Gilen Mar-Barrutia3, José Miguel Martinez-Llorente4, Severina Domínguez5, Juan José García-Albás6, Arantzazu Arrospide7. 1. Unidad de Investigación AP-OSI, Hospital Alto Deba, Arrasate-Mondragón, Gipuzkoa, España; Unidad de Gestión Sanitaria, Hospital Alto Deba, Arrasate-Mondragón, Gipuzkoa, España; Red de Investigación en Servicios de Salud y Enfermedades Crónicas (REDISSEC), Bilbao, Bizkaia, España; Instituto Biodonostia, Donostia-San Sebastián, Gipuzkoa, España. Electronic address: javier.marmedina@osakidetza.net. 2. Servicio de Cirugía, Hospital Universitario de Álava, Vitoria-Gasteiz, Álava, España. 3. Unidad de Investigación AP-OSI, Hospital Alto Deba, Arrasate-Mondragón, Gipuzkoa, España. 4. Departamento de Contabilidad, Hospital Alto Deba, Arrasate-Mondragón, Gipuzkoa, España. 5. Servicio de Oncología Médica, Hospital Universitario de Álava, Vitoria-Gasteiz, Álava, España. 6. Servicio de Farmacia, Hospital Universitario de Álava, Vitoria-Gasteiz, Álava, España. 7. Unidad de Investigación AP-OSI, Hospital Alto Deba, Arrasate-Mondragón, Gipuzkoa, España; Red de Investigación en Servicios de Salud y Enfermedades Crónicas (REDISSEC), Bilbao, Bizkaia, España; Instituto Biodonostia, Donostia-San Sebastián, Gipuzkoa, España.
Abstract
INTRODUCTION: The aim of this study was to measure the cost of treatment of colorectal cancer in the Basque public health system according to the clinical stage. METHODS: We retrospectively collected demographic data, clinical data and resource use of a sample of 529 patients. For stagesi toiii the initial and follow-up costs were measured. The calculation of cost for stageiv combined generalized linear models to relate the cost to the duration of follow-up based on parametric survival analysis. Unit costs were obtained from the analytical accounting system of the Basque Health Service. RESULTS: The sample included 110 patients with stagei, 171 with stageii, 158 with stageiii and 90 with stageiv colorectal cancer. The initial total cost per patient was 8,644€ for stagei, 12,675€ for stageii and 13,034€ for stageiii. The main component was hospitalization cost. Calculated by extrapolation for stageiv mean survival was 1.27years. Its average annual cost was 22,403€, and 24,509€ to death. The total annual cost for colorectal cancer extrapolated to the whole Spanish health system was 623.9million€. CONCLUSIONS: The economic burden of colorectal cancer is important and should be taken into account in decision-making. The combination of generalized linear models and survival analysis allows estimation of the cost of metastatic stage.
INTRODUCTION: The aim of this study was to measure the cost of treatment of colorectal cancer in the Basque public health system according to the clinical stage. METHODS: We retrospectively collected demographic data, clinical data and resource use of a sample of 529 patients. For stagesi toiii the initial and follow-up costs were measured. The calculation of cost for stageiv combined generalized linear models to relate the cost to the duration of follow-up based on parametric survival analysis. Unit costs were obtained from the analytical accounting system of the Basque Health Service. RESULTS: The sample included 110 patients with stagei, 171 with stageii, 158 with stageiii and 90 with stageiv colorectal cancer. The initial total cost per patient was 8,644€ for stagei, 12,675€ for stageii and 13,034€ for stageiii. The main component was hospitalization cost. Calculated by extrapolation for stageiv mean survival was 1.27years. Its average annual cost was 22,403€, and 24,509€ to death. The total annual cost for colorectal cancer extrapolated to the whole Spanish health system was 623.9million€. CONCLUSIONS: The economic burden of colorectal cancer is important and should be taken into account in decision-making. The combination of generalized linear models and survival analysis allows estimation of the cost of metastatic stage.
Authors: Arantzazu Arrospide; Isabel Idigoras; Javier Mar; Harry de Koning; Miriam van der Meulen; Myriam Soto-Gordoa; Jose Miguel Martinez-Llorente; Isabel Portillo; Eunate Arana-Arri; Oliver Ibarrondo; Iris Lansdorp-Vogelaar Journal: BMC Cancer Date: 2018-04-25 Impact factor: 4.430